A detailed history of Royal Bank Of Canada transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 12,451 shares of VIR stock, worth $92,635. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,451
Previous 10,415 19.55%
Holding current value
$92,635
Previous $92,000 1.09%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $14,781 - $21,785
2,036 Added 19.55%
12,451 $93,000
Q2 2024

Aug 14, 2024

BUY
$7.63 - $12.66 $37,737 - $62,616
4,946 Added 90.44%
10,415 $92,000
Q1 2024

Nov 05, 2024

SELL
$8.6 - $11.9 $42,535 - $58,857
-4,946 Reduced 47.49%
5,469 $55,000
Q1 2024

May 15, 2024

SELL
$8.6 - $11.9 $194,618 - $269,297
-22,630 Reduced 80.54%
5,469 $55,000
Q4 2023

Feb 14, 2024

BUY
$7.76 - $10.29 $76,373 - $101,274
9,842 Added 53.91%
28,099 $282,000
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $50,992 - $137,354
5,579 Added 44.01%
18,257 $171,000
Q2 2023

Aug 14, 2023

BUY
$23.2 - $27.29 $86,141 - $101,327
3,713 Added 41.42%
12,678 $310,000
Q1 2023

May 15, 2023

SELL
$22.26 - $30.85 $116,486 - $161,438
-5,233 Reduced 36.86%
8,965 $208,000
Q4 2022

Feb 14, 2023

BUY
$19.96 - $28.22 $201,057 - $284,260
10,073 Added 244.19%
14,198 $359,000
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $9,312 - $15,861
510 Added 14.11%
4,125 $79,000
Q2 2022

Aug 15, 2022

SELL
$19.08 - $26.7 $183,893 - $257,334
-9,638 Reduced 72.72%
3,615 $92,000
Q1 2022

May 16, 2022

SELL
$21.19 - $40.01 $15,362 - $29,007
-725 Reduced 5.19%
13,253 $341,000
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $425,156 - $741,723
13,728 Added 5491.2%
13,978 $585,000
Q2 2021

Aug 16, 2021

BUY
$38.75 - $51.0 $9,687 - $12,750
250 New
250 $12,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $987M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.